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Abstract
Background Even though most patients who undergo resection of pancreatic adenocarcinoma have T3 disease with
extra-pancreatic tumor extension, T3 disease is not currently classified by tumor size. The aim of this study was to
modify the current TNM classification of pancreatic adenocarcinoma to reflect the influence of tumor size.
Methods A total of 847 consecutive pancreatectomy patients were recruited from multiple centers. Optimum tumor
size cutoff values were calculated by receiver operating characteristics analysis for tumors limited to the pancreas
(T1/2) and for T3 tumors. In our modified TNM classification, stage II was divided into stages IIA (T3aN0M0), IIB
(T3bN0M0), and IIC (T1-3bN1M0) using tumor size cutoff values. The usefulness of the new classification was
compared with that of the current classification using Akaike’s information criterion (AIC).
Results The optimum tumor size cutoff value distinguishing T1 andT2was 2 cm,while T3was divided into T3a and T3b at a
tumor size of 3 cm. The median survival time of the stages IIA, IIB, and IIC were 44.7, 27.6, and 20.3 months, respectively.
There were significant differences of survival between stages IIA and IIB (P = 0.02) and between stages IIB and IIC
(P = 0.03).Thenewclassification showedbetter performance comparedwith the current classificationbasedon theAICvalue.
Conclusions This proposed new TNM classification reflects the influence of tumor size in patients with extra-
pancreatic tumor extension (T3 disease), and the classification is useful for predicting mortality.
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Introduction
Pancreatic adenocarcinoma is the most lethal common
cancer and the eighth leading cause of cancer-related death
in men and the ninth leading cause of death in women
throughout the world [1]. It has a very poor prognosis, with
a 1-year survival rate of 25% and 5-year survival rate of
5%. Surgical resection is the only potential curative ther-
apy for the tumor; however, only 15–20% of patients are
considered to be candidates for resection because of an
advanced stage at the time of diagnosis [2]. Many previous
studies on the outcomes after curative resection of pan-
creatic adenocarcinoma have revealed that tumor size is an
independent prognostic factor, along with lymph node
metastasis and the surgical margin after curative resection
of the tumor [3–13]. In the current TNM classification of
the International Union Against Cancer (UICC) and the
American Joint Committee on Cancer (AJCC), tumors
limited to the pancreas are divided into T1 and T2 by tumor
size (2 cm). On the other hand, there is no classification for
tumor sizes extending beyond the pancreas (T3 and T4),
despite the fact that most pancreatic adenocarcinomas that
are resected are pathologically staged to T3 after surgery
[14, 15].
In the present study, we reviewed all data from patients
with pancreatic adenocarcinoma who had undergone pan-
createctomy with curative intent to calculate tumor size
cutoff values (Tco values) for tumors extending beyond the
Fig. 1 Flow diagram of the
present study
pancreas. We developed a modified TNM classification
that incorporated the Tco values for T3 disease and sta-
tistically evaluated the usefulness of our proposed new
TNM classification.
Patients and methods
Data were collected for a total of 1451 consecutive patients
with pancreatic adenocarcinomas who underwent pancre-
atectomy with curative intent between 2001 and 2012 at
seven high-volume surgical institutions in Japan (Tokyo
Metropolitan Komagome Hospital, Hiroshima University
Hospital, Nara Medical University Hospital, Tohoku
University Hospital, Kansai Medical University Hospital,
Kobe University Hospital, and Wakayama Medical
University Hospital). All patients underwent R0 or R1
pancreatectomy and had a confirmed pathological diagno-
sis. Of the 1451 patients, we excluded 37 patients with
initially unresectable tumors who received pancreatectomy
after chemotherapy or chemoradiotherapy, 14 patients with
mucinous carcinoma, 13 patients with anaplastic carci-
noma, and 257 patients whose pathological tumor size was
not recorded. In addition, 283 patients with resectable or
borderline resectable tumors who received neoadjuvant
therapy were excluded because it was considered difficult
to accurately measure tumor size due to the effect of such
treatment. The remaining 847 patients were reviewed in
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this study (Fig. 1). In each patient, pathological TNM
classification was performed according to the TNM clas-
sification of malignant tumors published by the UICC (7th
edition). The longest dimension measured by histopatho-
logical examination was defined as the tumor size. Tumor
resectability was classified according to the National
Comprehensive Cancer Network (NCCN) guideline [16].
Overall survival was defined as the interval from the date
of surgery to the last follow-up date or death. Statistical
analyses were performed using EZR, which is a graphical
user interface for R version 2.13.0 (R Foundation for Sta-
tistical Computing, Vienna, Austria) [17], and differences
were considered significant at P\ 0.05. The ethics review
board of each participating hospital approved this study.
Fig. 2 a Calculation of the cutoff value for tumor size (Tco value) in
patients with tumors limited to the pancreas by receiver operating
characteristics (ROC) analysis using tumor size as an independent
variable and the 3-year survival as the outcome. The optimum cutoff
point was defined as that with the highest sensitivity plus specificity.
Tumor size data for 90 patients (48 with T1 and 42 with T2 disease)
were analyzed, and the Tco value was calculated to be 2.1 cm. As a
result, the Tco value dividing T1 and T2 in the new TNM
classification was set at 2 cm. b–d Calculation of the cutoff Tco
value in patients with tumors extending beyond the pancreas by ROC
analysis using tumor size as an independent variable and the 1-, 2-,
and 3-year survival as outcomes. Tumor size data for 755 patients
with T3 disease were analyzed, and the Tco values were calculated
as 3.0, 3.0, and 3.0 cm, respectively. Accordingly, the Tco value
dividing T3a and T3b in the new TNM classification was set as 3 cm
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Calculation of tumor size cutoff values (Tco values)
Tumor size data for 90 patients (48 with T1 disease and 42
with T2 disease) were analyzed to determine the optimum
Tco value for tumors limited to the pancreas. Receiver
operating characteristics (ROC) analysis was performed by
drawing ROC curves with tumor size as an independent
variable and the 3-year survival as the outcome. In addi-
tion, the tumor size data for 676 patients with T3 disease
except M1 patients were analyzed to determine the opti-
mum Tco value for tumors extending beyond the pancreas,
by drawing ROC curves with tumor size as an independent
variable and the 1-, 2-, and 3-year survival as outcomes.
The optimum cutoff point was defined as that with the
highest sensitivity plus specificity. Two patients with T4
disease were excluded from this analysis of Tco values for
tumors extending beyond the pancreas.
Proposed new TNM classification based on Tco
values
To define the new T category, tumors limited to the pan-
creas were reclassified as T1 or T2 using our new Tco
value for these tumors, while tumors extending beyond the
pancreas (T3 in the current TNM classification) were
reclassified as T3a or T3b using our Tco value for such
tumors. Consequently, in our proposed new TNM classi-
fication, stages IA and IB remain as T1N0M0 and
T2N0M0, respectively. On the other hand, the current stage
IIA (T3N0M0) becomes stage IIA (T3aN0M0) and stage
Table 1 Univariate and multivariate survival analyses based on a tumor size of 2 cm, N category status, and M category status for patients with
tumors limited to the pancreas (T1 or T2) (n = 90)
Variables No. of patients (%) MST (months) Univariate analysis Multivariate analysis
P value Hazard ratio (95% CI) P value Hazard ratio (95% CI)
Tumor size (cm) 0.002 2.63 (1.41–4.91) 0.005 2.45 (1.32–4.56)
B2 49 (54.4) 86.3
[2 41 (45.6) 33.5
N category 0.024 1.97 (1.08–3.54) 0.048 1.83 (1.01–3.32)
No 59 (65.6) 70.2
Yes 31 (34.4) 33.5
M category 0.553 0.55 (0.08–4.03) – –
No 87 (96.7) 55.1
Yes 3 (3.3) 35.2
MST median survival time, CI confidence interval
Table 2 Univariate and multivariate survival analyses based on a tumor size of 3 cm, N category status, and M category status for patients with
tumors extending beyond the pancreas (T3) (n = 755)
Variables No. of patients (%) MST (months) Univariate analysis Multivariate analysis
P value Hazard ratio (95%CI) P value Hazard ratio (95%CI)
Tumor size (cm) \0.001 1.68 (1.39–2.03) \0.001 1.46 (1.20–1.77)
\3 274 (36.3) 30.3
C3 481 (63.7) 17.5
N category \0.001 1.97 (1.58–2.45) \0.001 1.72 (1.37–2.16)
No 192 (25.4) 35.7
Yes 563 (74.6) 18.4
M category \0.001 1.53 (1.22–1.93) 0.077 1.24 (0.98–1.56)
No 647 (85.7) 21.9
Yes 108 (14.3) 16.2
MST median survival time, CI confidence interval
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IIB (T3bN0M0), and the stage IIB (T1-3N1M0) changes to
stage IIC (T1-3bN1M0).
Evaluation of the new TNM classification
NewTco valueswere validated separately for tumors limited to
the pancreas (n = 90) and tumors extending beyond the pan-
creas (n = 755). Overall survival was compared between two
cohorts divided at these new Tco values by univariate analysis
with the log-rank test, and it was also compared between two
cohorts categorized according to lymph node metastasis (N
category of the TNM classification) or distant metastasis (M
category of the TNM classification). The hazard ratio and its
95% confidence intervals were estimated using univariate and
multivariate Cox’s proportional hazards models.
After reclassifying the 847 patients according to our new
TNM classification, clinicopathological factors (age, gen-
der, tumor site, tumor resectability, operating time, intra-
operative blood loss, preoperative serum CA19-9 level,
surgical margin, tumor histology, and postoperative adju-
vant chemotherapy) were compared between stage IA
(n = 36) and stage IB (n = 22) with a t test or Fisher’s exact
test and were also compared among stages IIA (n = 103),
IIB (n = 85), and IIC (n = 488) using an analysis of vari-
ance or Fisher’s exact test. To evaluate the usefulness of our
modifications, survival curves based on the new or current
TNM classification were constructed with the Kaplan–
Meier method and compared using the log-rank test for each
two-group comparison. In addition, the performance of the
new and current classifications was compared using
Akaike’s information criterion (AIC) [18], which is a cri-
terion for selecting a suitable model. It is often used to
compare the goodness of fit between the built models. The
model with the smaller AIC value is deemed a better fit.
Results
Tumor size cutoff values (Tco values)
The optimum Tco value for tumors limited to the pancreas
was calculated to be 2.1 cm based on the ROC curve for
Table 3 Comparison of clinicopathological characteristics between stage IA and stage IB
Parameter Stage IA (T1N0M0) (n = 36) Stage IB (T2N0M0) (n = 22) Total (n = 58) P value
Age (years) 68.6 ± 8.5 66.5 ± 7.7 67.8 ± 8.2 0.358
Gender
Male 18 (50.0) 14 (63.6) 32 0.75
Female 18 (50.0) 8 (36.4) 26
Tumor location
Proximal 23 (63.9) 10 (45.5) 33 0.27
Distal 13 (36.1) 11 (50.0) 24
Other 0 (0) 1 (0.5) 1
NCCN resectability
R 33 (91.7) 21 (95.5) 54 1
BR 3 (8.3) 1 (4.5) 4
Operating time (min) 401.3 ± 131.6 391.2 ± 140.8 397.5 ± 133.9 0.79
Intraoperative blood loss (mL) 880.4 ± 626.9 1097.9 ± 777.4 961.9 ± 688.5 0.26
Serum level of CA19-9 (U/mL) 127.7 ± 345.5 199.9 ± 258.9 155.3 ± 314.7 0.41
Surgical margin
Positive 1 (2.7) 4 (18.2) 5 0.06
Negative 35 (97.3) 18 (81.8) 53
Tumor histology 1
Papillary 2 (5.6) 2 (9.1) 4
Well-differentiated 11 (30.6) 6 (27.3) 17
Moderately differentiated 23 (63.9) 10 (45.5) 33
Poorly differentiated 0 (0) 4 (18.2) 4
Adenosquamous 0 (0) 0 (0) 0
Adjuvant chemotherapy
Yes 26 (72.2) 17 (77.3) 43 0.76
No 10 (27.8) 5 (22.7) 15
NCCN National Comprehensive Cancer Network, R resectable, and BR borderline resectable
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3-year survival, and the area under the curve (AUC) was
0.69 (95% confidence interval, 0.57–0.81; Fig. 2a).
Therefore, the Tco value dividing T1 from T2 in our new
TNM classification was set as 2 cm, which was identical to
that in the current TNM classification. The optimum Tco
values for tumors extending beyond the pancreas were
calculated from the ROC curves for 1-, 2-, and 3-year
survival as 3.0, 3.0, and 3.0, respectively (Fig. 2b–d). The
AUC values were 0.61 (95% confidence interval,
0.57–0.66), 0.60 (0.56–0.65), and 0.61 (0.55–0.66),
respectively. Accordingly, the Tco value dividing T3a from
T3b in the new TNM classification was set as 3 cm.
Usefulness of the new TNM classification
Regarding tumors limited to the pancreas, univariate
analysis revealed a significant difference in overall survival
between two cohorts divided at a Tco value of 2 cm (T1
and T2) as well as between two cohorts separated by N
category status. Multivariate analysis indicated that the Tco
value of 2 cm (hazard ratio, 2.45; 95% confidence interval,
1.32–4.56; P = 0.005) and the N category (hazard ratio,
1.83; 95% confidence interval, 1.01–3.32; P = 0.048) were
both independent prognostic factors for tumors limited to
the pancreas, with a Tco value of 2 cm being a more
important prognosticator than the N category (Table 1).
Regarding tumors extending beyond the pancreas, uni-
variate analysis revealed significant differences of overall
survival between two cohorts divided at a Tco value of
3 cm (T3a and T3b), between two cohorts separated by N
category status, and between two cohorts divided by M
category status. Multivariate analysis indicated that the Tco
value of 3 cm (hazard ratio, 1.46; 95% confidence interval,
1.20–1.77; P\ 0.001) and N category (hazard ratio, 1.72;
Table 4 Comparison of clinicopathological characteristics among patients in the proposed new stages IIA, IIB, and IIC
Parameter New stage IIA (T3aN0M0)
(n = 103)
New stage IIB
(T3bN0M0) (n = 85)
New stage IIC (T1-
3bN1M0) (n = 488)
Total (n = 676) P value*
Age (years) 71.0 ± 8.3 68.8 ± 8.9 67.2 ± 10.2 67.9 ± 9.9 0.001
Gender 0.83
Male 56 (54.4) 50 (58.8) 277 (56.8) 383
Female 47 (45.6) 35 (41.3) 211 (43.2) 293
Tumor location 0.014
Proximal 70 (68.0) 47 (55.3) 355 (72.7) 472
Distal 33 (32.0) 33 (38.8) 123 (25.2) 189
Other 0 (0) 5 (5.9) 10 (2.0) 15
NCCN resectability \0.01
R 84 (81.6) 52 (61.2) 291 (59.6) 427
BR 19 (18.4) 33 (38.8) 197 (40.4) 249
Operating time (min) 407.6 ± 154.0 433.5 ± 195.4 448.2 ± 155.5 440.3 ± 161.2 0.066
Intraoperative blood
loss (mL)
998.1 ± 737.9 1450.4 ± 1579.6 1253.6 ± 1043.3 1239.6 ± 1092.2 0.018
Serum level of CA19-
9 (U/mL)
281.1 ± 525.1 545.3 ± 970.7 914.1 ± 3465.9 762.1 ± 2941.2 0.142
Surgical margin 0.054
Positive 17 (16.5) 22 (25.9) 136 (27.9) 175
Negative 86 (83.5) 63 (74.1) 352 (72.1) 501
Tumor histology 0.015
Papillary 3 (2.9) 1 (1.2) 6 (1.2) 10
Well-diff 31 (30.1) 24 (28.2) 114 (23.4) 169
Moderately diff 62 (60.2) 44 (51.8) 315 (64.5) 421
Poorly diff 7 (6.8) 9 (10.6) 43 (8.8) 49
Adenosquamous 0 (0) 7 (8.2) 10 (2.0) 17
Adjuvant
chemotherapy
0.255
Yes 88 (85.4) 65 (76.5) 384 (79.2) 537
No 15 (14.9) 20 (23.5) 101 (20.8) 136
NCCN National Comprehensive Cancer Network, R resectable, BR borderline resectable, and diff differentiated
* P value is calculated using analysis of variance (ANOVA) for continuous variables and Fisher’s exact test for categorical variables
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95% confidence interval, 1.37–2.16; P\ 0.001) were both
independent prognostic factors for tumors extending
beyond the pancreas, although the N category was more
important than the Tco value (Table 2).
After reclassifying the 847 patients according to our new
TNM classification, the number of patients in stages IA and
IB remained at 36 and 22, respectively, while the number
of patients in our new stages IIA, IIB, and IIC was 103, 85,
and 488, respectively. Comparison of clinicopathological
factors between stages IA and IB failed to identify any
significant factors that could support the validity of this
classification (Table 3). Comparison of clinicopathological
factors among the new stages IIA, IIB, and IIC revealed
that there were significantly more borderline
resectable patients (P = 0.003), significantly larger intra-
operative blood loss (P = 0.01), and a significantly higher
preoperative serum level of CA19-9 in new stage IIB than
new stage IIA, while the frequency of distal pancreatic
tumors was significantly higher in new stage IIC than new
stage IIB (Table 4).
Comparison of overall survival showed no significant
difference between stages IA and IB, but there was a sig-
nificant difference between current stages IIA and IIB
(Fig. 3a), as well as significant differences between new
stages IIA and IIB and between new stages IIB and IIC
(Fig. 3b).
Table 5 shows the results from the multivariate Cox’s
analysis using the new and current classifications as a
factor. According to the left half of Table 5, the new
classification was significantly associated with overall
survival, even when the prognostic factors were adjusted.
In the right half of Table 5, the current classification was
also significant; however, the AIC for the new classifica-
tion was smaller than that for the current classification.
This result indicated that the new classification outper-
forms the current classification.
Fig. 3 a Actuarial survival curves of 847 patients according to the
current TNM classification. The 5-year survival rate was not
significantly different between stage IA (100%) and stage IB
(43.6%; P = 0.08) or between stage IB and stage IIA (34.4%;
P = 0.66), while there was a significant difference between stages
IIA and IIB (16.0%; P\ 0.01). b Actuarial survival curves of 847
patients according to the new TNM classification. The 5-year
survival rate was not significantly different between stage IB (43.6%)
and the new stage IIA (44.0%; P = 0.79), while there were
significant differences between new stages IIA and IIB (21.1%;
P\ 0.02) and between new stages IIB and IIC (16.0%; P = 0.03).
The P value was calculated using the log-rank test for each two-
group comparison
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Discussion
Many previous studies have found that tumor size was an
independent prognostic factor for pancreatic adenocarci-
nomas, but the Tco value used to evaluate the significance
of tumor size has varied among them. Based on a Tco value
of 3 cm, Yeo et al. [3], Benassai et al. [8], and Winter et al.
[13] reported that tumor size was an independent prog-
nostic factor in pancreatoduodenectomy patients. Moon
et al. [10] also employed 3 cm in a study that identified
tumor size as an independent prognostic factor in patients
who had undergone resection of pancreatic adenocarci-
noma by any mode of pancreatectomy. However, Geer
et al. [11] and Lim et al. [9] employed 2.5 cm and 2 cm as
the Tco values, respectively, in studies of patients who
underwent R0/1 pancreatectomy, while Meyer et al. [12]
employed 2 cm as the Tco value to evaluate patients
undergoing R0 pancreatectomy. All these studies showed
that tumor size was an independent prognostic factor after
resection of a pancreatic adenocarcinoma. Thus, a range
from 2 to 3 cm has been employed as the Tco value in
previous studies. Of these studies, only two described the
stage distribution of the patients. In the study of Meyer
et al. [12], 10.8% of the patients were in stages IA or IB
versus only 4.3% in the study of Moon et al. [11]. In the
former study, which recruited a higher percentage of
patients with tumors limited to the pancreas, the Tco value
was set at 2 cm, while it was 3 cm in latter study. How-
ever, the rationale for setting the Tco value was not
explained in most of the previous reports. In a few studies,
significant differences of survival were found by compar-
ing different candidate Tco values set at regular intervals,
and the Tco value with the lowest P value was selected
[3, 9, 11]. However, none of the previous studies employed
ROC analysis to determine the Tco value as we did this
time. ROC curves can be used to statistically detect the
optimum Tco value without researcher bias, which is
considered to be an advantage of the present study.
In this study, multivariate analysis revealed that tumor
size was the most significant independent prognostic factor
for patients with tumors limited to the pancreas, but the
Tco value distinguishing T1 and T2 was the same as in the
Table 5 Multivariate Cox’s regression analysis for overall survival in patients in stage II
Effect and level New stage Current stage
Adjusted HR (95% CI) P Adjusted HR (95% CI) P
Stage \0.001 \0.001
2B vs 2A 1.52 (0.96,2.39) 0.072 1.94 (1.50,2.52) \0.001
2C vs 2A 2.37 (1.67,3.38) \0.001 – –
Age (10 yrs) 1.36 (1.20,1.54) \0.001 1.35 (1.19,1.54) \0.001
Gender, M vs F 1.04 (0.82,1.32) 0.77 1.03 (0.81,1.31) 0.82
Tumor location, proximal vs distal 0.83 (0.62,1.12) 0.22 0.82 (0.62,1.10) 0.19
NCCN resectability, R vs BR 1.02 (0.79,1.31) 0.87 1.00 (0.77,1.28) 0.97
Operating time (60 min) 1.02 (0.96,1.08) 0.47 1.02 (0.96,1.08) 0.49
Intraoperative blood loss (1000 mL) 1.22 (1.08,1.37) \0.001 1.24 (1.10,1.39) \0.001
Serum level of CA19-9 (1000 U/mL) 1.03 (1.00,1.06) 0.047 1.03 (1.00,1.06) 0.045
Surgical margin, positive vs negative 1.12 (0.87,1.45) 0.37 1.14 (0.89,1.47) 0.30
Tumor histology \0.001 \0.001
Well-diff vs adsq 0.22 (0.11,0.46) \0.001 0.21 (0.10,0.43) \0.001
Moderately diff vs adsq 0.32 (0.16,0.63) 0.001 0.29 (0.15,0.58) \0.001
Poorly diff vs adsq 0.44 (0.21,0.94) 0.034 0.42 (0.20,0.88) 0.022
Papillary vs adsq 0.16 (0.06,0.48) 0.001 0.15 (0.05,0.43) \0.001
Adjuvant chemotherapy, Y vs N 0.57 (0.44,0.74) \0.001 0.57 (0.43,0.74) \0.001
T category 0.055 0.061
2 vs 1 3.65 (1.15,11.63) 0.028 3.61 (1.13,11.48) 0.030
3 vs 1 3.39 (1.24,9.27) 0.017 3.31 (1.21,9.05) 0.019
No. of analysis data 543 543
AIC 3674.4 3675.6
NCCN National Comprehensive Cancer Network, R resectable, BR borderline resectable, diff differentiated, adsq adenosquamous, and AIC
Akaike’s information criterion (smaller is better)
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current TNM classification, and there was no significant dif-
ference in overall survival between stages IA and IB. Because
of the small number of patients with tumors limited to the
pancreas in this study, it was difficult to assess the correlation
of tumor size with their prognosis. Among patients with
tumors extending beyond the pancreas, the preoperative
serum level of CA19-9 was significantly higher in new stage
IIB than new stage IIA. This finding corresponded to previous
reports that a high preoperative serum level of CA19-9 is a
significant adverse prognostic factor [19, 20]. In addition, the
proportion of patients with borderline resectable tumors was
significantly larger in new stage IIB than IIA, indicating that
tumor size is strongly related to tumor invasion of the main
arterial trunks (celiac axis and/or superior mesenteric artery)
[21]. These results provide support for our proposed new
TNM classification.
Many studies have found that N category status is a
significant independent prognostic factor [3, 8, 9, 11, 12],
although there have been a few exceptions [7, 10]. The N
category status was a significant independent prognostic
factor for patients who underwent R0/1 pancreatectomy in
this study as well. Therefore, the current stage IIB (T1-
3N1M0) was defined as the proposed new stage IIC (T1-
3bN1M0), basically maintaining the composition of all
three categories. The resulting new TNM classification was
considered to be useful because there was a significant
difference of survival between stages IIA and IIB as well as
between stages IIB and IIC.
According to the NCCN guidelines of 2015, preopera-
tive staging laparoscopy is recommended for high-risk
patients (borderline resectable disease, markedly elevated
CA19-9, large primary tumors, or large regional lymph
nodes) [22]. Since CA19-9[ 150 U/mL and tumor
size[ 3 cm are considered as surrogate markers for pre-
operative staging laparoscopy, we insist on the necessity of
performing preoperative staging laparoscopy to the patients
with our new stage IIB or higher to check for unre-
sectability prior to the surgery [23].
In conclusion, the proposed new TNM classification
of pancreatic cancer developed in this study reflects
tumor size, which is an important prognostic factor in
patients with tumors extending beyond the pancreas
(current T3), and they form the largest group undergoing
pancreatectomy. The present results require validation by
a large-scale study employing ROC analysis in the
future.
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